



November 09, 2018

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Sub : Disclosure of the Outcome of the Board Meeting under Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

**Ref : HealthCare Global Enterprises Limited (“the Company”)
(NSE Scrip Code: HCG/ BSE Scrip Code: 539787)**

Dear Sir/Madam,

We wish to inform you that the Board of Directors of the Company (“Board”), at their meeting held on this day, the 9th November 2018, *inter alia*, has considered and approved the following agenda:

1. Unaudited Financial Results of the Company, both Standalone and Consolidated (Limited Review), for the quarter and half year ended September 30, 2018, and
2. Issue and allotment of 32,940 (Thirty Two Thousand Nine Hundred Forty) equity shares of the Company of Rs. 10 each, upon exercise of Employee Stock Options under Employee Stock Option Scheme, 2014 of the Company.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Unaudited Financial Results of the Company (Standalone and Consolidated) for the quarter and half year ended September 30, 2018.

The Meeting of the Board concluded at 4.35 P.M.

Request you to take this on record.

For HealthCare Global Enterprises Limited

Sunu Manuel
Company Secretary & Compliance Officer

Encl: as above

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489

BSR & Co. LLP

Chartered Accountants

Maruthi Info-Tech Centre
11-12/1, B Block, 2nd Floor
Inner Ring Road, Koramangala
Bangalore 560 071 India

Telephone +91 80 7134 7000
Fax +91 80 7134 7999

Limited review report on unaudited quarterly standalone financial results and standalone year-to-date results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of HealthCare Global Enterprises Limited

We have reviewed the accompanying statement of unaudited standalone financial results ('Statement') of HealthCare Global Enterprises Limited ('the Company') for the quarter ended 30 September 2018 and the year-to-date results for the period from 1 April 2018 to 30 September 2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* specified under section 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

for BSR & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Amit Somani

Amit Somani
Partner
Membership No. 060154

Place: Bengaluru
Date: 9 November 2018

HealthCare Global Enterprises Limited
CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2018

(Rs. in Lakhs except share data)

| Sl. No. | Particulars | 3 months ended | Preceding 3 months ended | Corresponding 3 months ended in the | Year to date | Year to date | Previous year |
|---------|---|-------------------|--------------------------|-------------------------------------|-----------------|-----------------|---------------|
| | | 30 September 2018 | 30 June 2018 | months ended in the | figures for the | figures for the | ended |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| | | | | (Refer note 4) | | (Refer note 4) | |
| 1 | Income | | | | | | |
| | (a) Revenue from operations | 16,152 | 15,401 | 15,032 | 31,553 | 28,752 | 58,627 |
| | (b) Income from government grant | 15 | 15 | - | 30 | - | 60 |
| | (c) Other income | 280 | 170 | 163 | 450 | 367 | 1,593 |
| | Total income | 16,447 | 15,586 | 15,195 | 32,033 | 29,119 | 60,280 |
| 2 | Expenses | | | | | | |
| | (a) Purchases of medical and non-medical items | 4,005 | 3,893 | 3,948 | 7,898 | 8,184 | 15,782 |
| | (b) Changes in inventories | (144) | (18) | (18) | (162) | (405) | (267) |
| | (c) Employee benefits expense | 3,198 | 3,031 | 3,017 | 6,229 | 5,706 | 11,559 |
| | (d) Finance costs | 1,444 | 974 | 612 | 2,418 | 1,107 | 2,680 |
| | (e) Depreciation and amortisation expense | 1,172 | 1,064 | 1,073 | 2,236 | 2,116 | 4,392 |
| | (f) Medical consultancy charges | 2,919 | 2,814 | 2,729 | 5,733 | 5,303 | 10,340 |
| | (g) Other expenses | 3,686 | 3,313 | 3,113 | 6,999 | 5,886 | 12,400 |
| | Total expenses | 16,280 | 15,071 | 14,474 | 31,351 | 27,897 | 56,886 |
| 3 | Profit before exceptional items and tax (1-2) | 167 | 515 | 721 | 682 | 1,222 | 3,394 |
| 4 | Exceptional items [refer note 3] | - | - | - | - | - | 294 |
| 5 | Profit before tax (3+4) | 167 | 515 | 721 | 682 | 1,222 | 3,688 |
| 6 | Tax expense | | | | | | |
| | - Current tax | 36 | 118 | 180 | 154 | 316 | 863 |
| | - Deferred tax | 22 | 66 | 44 | 88 | 100 | 335 |
| | Total tax expense | 58 | 184 | 224 | 242 | 416 | 1,198 |
| 7 | Profit for the period / year (5-6) | 109 | 331 | 497 | 440 | 806 | 2,490 |
| 8 | Other comprehensive income / expense | | | | | | |
| | (i) Items that will not be reclassified subsequently to profit or loss | | | | | | |
| | - Remeasurements of the defined benefit plans | - | - | - | - | - | (30) |
| | - Income tax effect on above | - | - | - | - | - | 10 |
| | (ii) Items that will be reclassified to profit or loss | | | | | | |
| | - Effective portion of loss on hedging instruments in a cash flow hedge | (400) | - | (29) | (400) | (29) | - |
| | - Income tax on (ii) above | 140 | - | 10 | 140 | 10 | - |
| | Other comprehensive expense for the period / year, net of tax | (260) | - | (19) | (260) | (19) | (20) |
| 9 | Total comprehensive income/(loss) for the period / year (7+8) | (151) | 331 | 478 | 180 | 787 | 2,470 |
| 10 | Paid-up equity share capital (Face value of Rs. 10 each) | 8,786 | 8,786 | 8,571 | 8,786 | 8,571 | 8,690 |
| 11 | Reserves, i.e., 'Other equity' | | | | | | 52,156 |
| 12 | Earnings per equity share (face value of Rs. 10 each) | Not annualised | Not annualised | Not annualised | Not annualised | Not annualised | Annualised |
| | (a) Basic | 0.12 | 0.38 | 0.57 | 0.50 | 0.94 | 2.89 |
| | (b) Diluted | 0.12 | 0.38 | 0.57 | 0.50 | 0.94 | 2.89 |
| | See accompanying notes to the Standalone Financial Results | | | | | | |



HealthCare Global Enterprises Limited
CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS AS AT 30 SEPTEMBER 2018

| STANDALONE BALANCE SHEET | | (Rs in Lakhs) | |
|--------------------------|---|----------------------------|------------------------|
| | | As at 30 September 2018 | As at 31 March 2018 |
| Particulars | | Unaudited | Audited |
| A | ASSETS | | |
| I | Non-current assets | | |
| | (a) Property, plant and equipment | 46,249 | 43,907 |
| | (b) Capital work in progress | 9,994 | 7,911 |
| | (c) Goodwill | 4,845 | 4,845 |
| | (d) Other intangible assets | 842 | 447 |
| | (e) Financial assets | | |
| | (i) Investments | 27,465 | 21,885 |
| | (ii) Loans | 5,487 | 3,383 |
| | (iii) Other financial assets | 937 | 2,935 |
| | (f) Deferred tax assets (net) | 956 | 910 |
| | (g) Income tax assets (net) | 2,657 | 1,747 |
| | (h) Other non-current assets | 5,012 | 3,493 |
| | Total non current assets | 104,444 | 91,463 |
| II | Current assets | | |
| | (a) Inventories | 1,870 | 1,710 |
| | (b) Financial assets | | |
| | (i) Trade receivables | 17,292 | 12,621 |
| | (ii) Cash and cash equivalents | 981 | 1,531 |
| | (iii) Bank balance other than cash and cash equivalents above | 25 | - |
| | (iv) Loans | 325 | 292 |
| | (v) Other financial assets | 2,332 | 1,814 |
| | (c) Other current assets | 2,306 | 1,795 |
| | Total current assets | 25,131 | 19,763 |
| | Total assets | 129,575 | 111,226 |
| B | EQUITY AND LIABILITIES | | |
| I | Equity | | |
| | (a) Equity share capital | 8,786 | 8,690 |
| | (b) Shares pending issuance (refer note 5) | - | 2,998 |
| | (c) Other equity | 55,426 | 52,156 |
| | Total equity | 64,212 | 63,844 |
| II | Liabilities | | |
| 1 | Non-current liabilities | | |
| | (a) Financials liabilities | | |
| | (i) Borrowings | 32,350 | 21,724 |
| | (ii) Other financial liabilities | 2,462 | 2,211 |
| | (b) Provisions | 416 | 373 |
| | (c) Other non-current liabilities | 1,033 | 1,002 |
| | Total non - current liabilities | 36,261 | 25,310 |
| 2 | Current liabilities | | |
| | (a) Financials liabilities | | |
| | (i) Borrowings | 6,274 | 174 |
| | (ii) Trade payables | 14,081 | 11,442 |
| | (iii) Other financial liabilities | 6,036 | 7,812 |
| | (b) Provisions | 564 | 520 |
| | (c) Other current liabilities | 2,147 | 2,124 |
| | Total current liabilities | 29,102 | 22,072 |
| | Total equity and liabilities | 129,575 | 111,226 |

See accompanying notes to the Standalone Financial Results



HealthCare Global Enterprises Limited
CIN : L15200KA1998PLC023489
 Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
 Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE PERIOD ENDED 30 SEPTEMBER 2018

Notes:

1 The statement of unaudited standalone financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company') for the quarter and six months ended 30 September 2018 has been reviewed by the Audit and Risk Management Committee and approved by the Board of Directors at their meeting held on 9 November 2018. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

The Statement has been subjected to limited review by the statutory auditor of the Company. The review report of the auditor is unqualified.

2 The statement of category wise utilisation of net proceeds from Initial Public Offer is:

| Category wise utilisation of net proceeds from Initial Public Offer | Amount proposed to be utilised | (Rs. in Lakhs) |
|---|--------------------------------|---|
| | | Actual utilisation upto 30 September 2018 |
| Purchase of medical equipment | 4,220 | - |
| Investment in IT software, services and hardware | 3,019 | 1,627 |
| Pre-payment of debt | 14,704 | 14,700 |
| General corporate purposes | 1,977 | 1,977 |
| Total | 23,920 | 18,304 |

| Details of unutilised funds as on 30 September 2018 | (Rs. in Lakhs) |
|---|----------------|
| Investment in fixed deposits | 2,453 |
| Amount parked in cash credit account | 3,163 |
| Total | 5,616 |

3 Exceptional items:

- a During the year ended 31 March 2018, the Company has entered into a business transfer agreement with Strand Life Sciences Private Limited ('Strand') dated 2 January 2018 for sale of its Triesta unit on slump sale basis for a lumpsum consideration of Rs. 2,400 lakhs for which the consideration is received in the form of 9,140,342 equity shares and 101,193 Series 1 Preference Shares of Strand resulting in a gain of Rs. 614 lakhs.
- b During the year ended 31 March 2018, the Delhi unit of the Company became non-operational. Net charge on account of write off of receivables is Rs. 218 lakhs and the charge due to write off of net fixed assets is Rs. 546 lakhs. The total charge due to this unit closure is Rs. 764 lakhs.
- c In accordance with the terms of share purchase agreement entered into with Regency Hospital Limited dated 28 March 2018, the Company sold its long-term investments in equity shares held in HCG Regency Oncology HealthCare Private Limited (HCG Regency) for a total consideration of Rs. 2,123 lakhs resulting in a gain of Rs. 444 lakhs. Pursuant to the above, HCG Regency has ceased to be subsidiary of the Company with effect from 29 March 2018. On account of a, b and c above, there is an exceptional gain of Rs.294 lakhs during the previous year ended 31 March 2018.
- 4 During the year ended 31 March 2018, HCG Pinnacle Oncology Private Limited, the wholly owned subsidiary of the Company ('Transferee Company'), has been merged with the Company ('Transferor Company') in accordance with the terms of a Scheme of Amalgamation approved by the Regional Director, Ministry of Corporate Affairs, Hyderabad dated 30 January 2018 ('the Scheme') with an appointed date of 1 April 2016. In line with Scheme and Ind AS 103, Business Combination requirement, the Company has considered the appointed date as 1 April 2016 and have considered the merger from the appointed date and accordingly have restated its results for the comparative quarters/periods including Earnings Per Share.

The impact of merger on the Statement are as follows:

| Particulars | (Rs. in Lakhs) | |
|----------------------------------|---|---|
| | for the quarter ended 30 September 2017 | for the year to date period ended 30 September 2017 |
| Revenue (including other income) | 386 | 721 |
| Total expenditure | 440 | 859 |
| Profit after tax | (8) | (80) |
| Basic earnings per share | (0.01) | (0.09) |
| Diluted earnings per share | (0.01) | (0.09) |

- 5 During the year ended 31 March 2018, the Company entered into a business transfer agreement with Dr. Gopichand ('Seller') dated 28 February 2018 for purchase of business undertaking owned and operated by the Seller in the name of City Cancer Centre ('CCC') located in Vijayawada. The Company has purchased the business on a slump sale basis for a lump sum consideration of Rs.5,200 lakhs to be settled partially through issue of equity shares of the Company and partially through cash. Accordingly, 934,500 equity shares of Rs. 10 at premium of Rs. 311 per share has been allotted to Dr. Gopichand, during the preceding quarter ended 30 June 2018 on preferential basis.
- 6 During the quarter ended 30 September 2018, Apex Criticare LLP, holding 49.90% stake in one of the subsidiary of the Company, Apex HCG Oncology Hospitals LLP (Apex LLP) retired from Apex LLP. Pursuant to this, the Company along with its wholly owned subsidiary, Niruja Product Development and Healthcare Research Private Limited holds 100% interest in Apex LLP.
- 7 The Company has a single operating segment of 'setting up and managing hospitals and medical diagnostic services'.
- 8 Effective 1 April 2018 the Company has adopted Ind AS 115 - 'Revenue from Contracts with Customers' using the cumulative effect method. Accordingly, comparative periods were not restated. Based on the assessment, there is no material impact consequent to adoption of the standard.

Bengaluru, 9 November 2018



For and on behalf of the Board of Directors

Dr. B. S. Ajai Kumar
 Chairman and CEO



B S R & Co. LLP

Chartered Accountants

Maruthi Info-Tech Centre
11-12/1, B Block, 2nd Floor
Inner Ring Road, Koramangala
Bangalore 560 071 India

Telephone +91 80 7134 7000
Fax +91 80 7134 7999

Limited review report on unaudited quarterly consolidated financial results and consolidated year-to-date results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of HealthCare Global Enterprises Limited

We have reviewed the accompanying statement of unaudited consolidated financial results ("Statement") of HealthCare Global Enterprises Limited (hereinafter referred to as "the Holding Company"), its subsidiaries (collectively referred to as 'the Group'), its associate and its joint venture as listed in Annexure 1 for the quarter ended 30 September 2018 and the year-to-date results for the period from 1 April 2018 to 30 September 2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these consolidated financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* specified under section 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the consolidated financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We did not review the financial information of four subsidiaries and one step down subsidiary included in the statement of unaudited consolidated financial results and consolidated year-to-date financial results, whose unaudited financial information reflect total revenue (including other income) of Rs. 586 lakhs and Rs. 914 lakhs for the quarter ended 30 September 2018 and period from 1 April 2018 to 30 September 2018, respectively and total assets of Rs. 15,592 lakhs as at 30 September 2018. The consolidated financial results also include the Group's share of net loss (and other comprehensive income/expense) of Rs. 153 lakhs and Rs. 345 lakhs for the quarter ended 30 September 2018 and period from 1 April 2018 to 30 September 2018, respectively in respect of an associate and a joint venture whose financial information have not been reviewed by us. These unaudited financial information has been reviewed by other auditors whose reports have been furnished to us, and our opinion on the unaudited consolidated financial results and the year-to-date results, to the extent they have been derived from such unaudited financial information is based solely on the report of such other auditors

Our conclusion on the Statement is not modified with respect to the reports of the other auditors.



Limited review report on unaudited quarterly consolidated financial results and consolidated year-to-date results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (continued)

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

for B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Amit Somani

Amit Somani
Partner
Membership No. 060154

Place: Bengaluru
Date: 9 November 2018

HealthCare Global Enterprises Limited

Annexure 1: List of entities consolidated as at 30 September 2018

| Sl. No. | Name of the Entity | Subsidiary/ Associate/ Joint Venture | Country of incorporation |
|---------|--|--|-----------------------------|
| 1 | BACC Healthcare Private Limited | Subsidiary | India |
| 2 | HCG Medi-Surge Hospitals Private Limited | Subsidiary | India |
| 3 | HCG Oncology LLP | Subsidiary | India |
| 4 | HealthCare Diwan Chand Imaging LLP | Subsidiary | India |
| 5 | HCG NCHRI Oncology LLP | Subsidiary | India |
| 6 | HCG EKO Oncology LLP | Subsidiary | India |
| 7 | APEX HCG Oncology Hospitals LLP | Subsidiary | India |
| 8 | HCG Manavata Oncology LLP | Subsidiary | India |
| 9 | Niruja Product Development & Healthcare Research Private Limited (formerly known as MIMS HCG Oncology Private Limited) | Subsidiary | India |
| 10 | HealthCare Global Senthil Multi Specialty Private Limited | Subsidiary | India |
| 11 | Malnad Hospital & Institute of Oncology Private Limited | Subsidiary | India |
| 12 | HCG Sun Hospitals LLP | Subsidiary | India |
| 13 | HCG (Mauritius) Private Limited | Step-down subsidiary | Mauritius |
| 14 | HealthCare Global (Africa) Private Limited Group (subsidiary till 30 June 2017) | Associate | Mauritius |
| 15 | Strand Life Sciences Private Limited (from 7 February 2018) | Joint Venture | India |

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2018

(Rs. in Lakhs except share data)

| Sl. No. | Particulars | 3 months ended | Preceding 3 months ended | Corresponding 3 months ended in the | Year to date | Year to date | Previous year |
|---------|---|-------------------|--------------------------|-------------------------------------|--------------------------------------|---------------------------------------|---------------|
| | | 30 September 2018 | 30 June 2018 | previous year | figures for the current period ended | figures for the previous period ended | ended |
| | | Unaudited | Unaudited | Unaudited | 30 September 2018 | 30 September 2017 | 31 March 2018 |
| | | | | | Unaudited | Unaudited | Audited |
| 1 | Income | | | | | | |
| | (a) Revenue from operations | 24,474 | 22,598 | 21,107 | 47,072 | 40,217 | 82,879 |
| | (b) Income from government grant | 58 | 58 | - | 116 | - | 190 |
| | (c) Other income | 226 | 94 | 190 | 320 | 432 | 1,280 |
| | Total income | 24,758 | 22,750 | 21,297 | 47,508 | 40,649 | 84,349 |
| 2 | Expenses | | | | | | |
| | (a) Purchases of medical and non-medical items | 5,829 | 5,079 | 4,678 | 10,908 | 10,102 | 19,664 |
| | (b) Changes in inventories | (311) | (102) | 139 | (413) | (737) | (693) |
| | (c) Employee benefits expense | 4,490 | 4,228 | 4,093 | 8,718 | 7,609 | 15,771 |
| | (d) Finance costs | 2,387 | 1,754 | 1,045 | 4,141 | 1,741 | 4,235 |
| | (e) Depreciation and amortisation expense | 2,063 | 1,973 | 1,670 | 4,036 | 3,194 | 7,146 |
| | (f) Medical consultancy charges | 5,107 | 4,795 | 4,460 | 9,902 | 8,524 | 17,422 |
| | (g) Other expenses | 6,067 | 5,601 | 4,630 | 11,668 | 8,662 | 19,023 |
| | Total expenses | 25,632 | 23,328 | 20,715 | 48,960 | 39,095 | 82,568 |
| 3 | Profit/ (loss) before share of loss of an associate / joint venture, exceptional items and tax (1-2) | (874) | (578) | 582 | (1,452) | 1,554 | 1,781 |
| 4 | Share of loss of an associate / joint venture, net of taxes | (153) | (192) | (39) | (345) | (39) | (140) |
| 5 | Profit / (loss) before exceptional items and tax (3+4) | (1,027) | (770) | 543 | (1,797) | 1,515 | 1,641 |
| 6 | Exceptional items [refer note 3] | - | - | 640 | - | 640 | 1,077 |
| 7 | Profit/(loss) before tax (5+6) | (1,027) | (770) | 1,183 | (1,797) | 2,155 | 2,718 |
| 8 | Tax expense | | | | | | |
| | - Current tax | 84 | 124 | 272 | 208 | 516 | 1,355 |
| | - Deferred tax | (347) | (261) | (71) | (608) | 49 | (331) |
| | Total tax expense | (263) | (137) | 201 | (400) | 565 | 1,024 |
| 9 | Profit / (loss) for the period / year (7-8) | (764) | (633) | 982 | (1,397) | 1,590 | 1,694 |
| 10 | Other comprehensive income / expense | | | | | | |
| | (i) Items that will not be reclassified subsequently to profit or loss | | | | | | |
| | - Remeasurements of the defined benefit plans | - | - | - | - | - | (25) |
| | - Exchange differences on translation of financial statements of foreign operations | 209 | - | - | 209 | - | - |
| | - Income tax effect on above | - | - | - | - | - | 10 |
| | (ii) Items that will be reclassified to profit or loss | | | | | | |
| | - Effective portion of loss on hedging instruments in a cash flow hedge | (400) | - | (29) | (400) | (29) | - |
| | - Income tax on (ii) above | 140 | - | 10 | 140 | 10 | - |
| | Other comprehensive expense for the period / year, net of taxes | (51) | - | (19) | (51) | (19) | (15) |
| 11 | Total comprehensive loss for the period / year (9+10) | (815) | (633) | 963 | (1,448) | 1,571 | 1,679 |
| | Profit / (loss) for the period / year attributable to: | | | | | | |
| | Equity holders of the Company | (647) | (341) | 1,001 | (988) | 1,474 | 2,052 |
| | Non-controlling interests | (117) | (292) | (19) | (409) | 116 | (358) |
| | Other comprehensive income / (loss) for the period / year attributable to | | | | | | |
| | Equity holders of the Company | (51) | - | (19) | (51) | (19) | (18) |
| | Non-controlling interests | - | - | - | - | - | 3 |
| | Total comprehensive income / (loss) for the period / year attributable to | | | | | | |
| | Equity holders of the Company | (698) | (341) | 982 | (1,039) | 1,455 | 2,034 |
| | Non-controlling interests | (117) | (292) | (19) | (409) | 116 | (355) |
| 12 | Paid-up equity share capital (Face value of Rs. 10 each) | 8,786 | 8,786 | 8,571 | 8,786 | 8,571 | 8,690 |
| 13 | Reserves, i.e., 'Other equity' | | | | | | 39,822 |
| 14 | Earnings per share (face value of Rs. 10 each) | Not annualised | Not annualised | Not annualised | Not annualised | Not annualised | Annualised |
| | (a) Basic | (0.74) | (0.39) | 1.17 | (1.12) | 1.72 | 2.38 |
| | (b) Diluted | (0.74) | (0.39) | 1.17 | (1.12) | 1.72 | 2.38 |
| | See accompanying notes to the Consolidated Financial Results | | | | | | |



BSR and



| CONSOLIDATED BALANCE SHEET | | (Rs in Lakhs) | |
|--|---|-------------------|----------------|
| Particulars | | As at | As at |
| | | 30 September 2018 | 31 March 2018 |
| | | Unaudited | Audited |
| A | ASSETS | | |
| I | Non-current assets | | |
| | (a) Property, plant and equipment | 80,264 | 71,257 |
| | (b) Capital work in progress | 14,395 | 17,397 |
| | (c) Goodwill | 10,934 | 10,934 |
| | (d) Other intangible assets | 955 | 581 |
| | (e) Investment in equity accounted investee | 4,693 | 4,804 |
| | (f) Financial assets | | |
| | (i) Investments | 677 | 513 |
| | (ii) Loans | 4,762 | 986 |
| | (iii) Other financial assets | 1,956 | 4,960 |
| | (g) Deferred tax assets (net) | 3,106 | 2,310 |
| | (h) Income tax assets (net) | 3,065 | 2,111 |
| | (i) Other non-current assets | 7,416 | 6,504 |
| | Total non current assets | 132,223 | 122,357 |
| II | Current assets | | |
| | (a) Inventories | 2,854 | 2,403 |
| | (b) Financial assets | | |
| | (i) Trade receivables | 16,457 | 12,844 |
| | (ii) Cash and cash equivalents | 2,799 | 2,880 |
| | (iii) Bank balance other than cash and cash equivalents above | 439 | - |
| | (iv) Loans | 395 | 312 |
| | (v) Other financial assets | 2,107 | 1,406 |
| | (c) Other current assets | 2,878 | 2,165 |
| | Total current assets | 27,929 | 22,010 |
| | Total assets | 160,152 | 144,367 |
| B | EQUITY AND LIABILITIES | | |
| I | Equity | | |
| | (a) Equity share capital | 8,786 | 8,690 |
| | (b) Shares pending issuance (refer note 4) | - | 2,998 |
| | (c) Other equity | 39,328 | 39,822 |
| | Equity attributable to equity holders of the Company | 48,114 | 51,510 |
| | Non- controlling interests | 6,189 | 6,392 |
| | Total equity | 54,303 | 57,902 |
| II | Liabilities | | |
| 1 | Non-current liabilities | | |
| | (a) Financials Liabilities | | |
| | (i) Borrowings | 46,659 | 37,243 |
| | (ii) Other financial liabilities | 2,019 | 9,157 |
| | (b) Provisions | 561 | 510 |
| | (c) Deferred tax liabilities (net) | 432 | 377 |
| | (d) Other non-current liabilities | 3,180 | 3,300 |
| | Total non - current liabilities | 52,851 | 50,587 |
| 2 | Current liabilities | | |
| | (a) Financials liabilities | | |
| | (i) Borrowings | 6,484 | 174 |
| | (ii) Trade payables | 16,826 | 14,249 |
| | (iii) Other financial liabilities | 25,567 | 17,644 |
| | (b) Provisions | 630 | 560 |
| | (c) Income tax liabilities (net) | 122 | 398 |
| | (d) Other current liabilities | 3,369 | 2,853 |
| | Total current liabilities | 52,998 | 35,878 |
| | Total equity and liabilities | 160,152 | 144,367 |
| See accompanying notes to the Consolidated Financial Results | | | |



BSR & Co.



STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2018

Notes:

- 1 The statement of unaudited consolidated financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company'), its subsidiaries (collectively referred to as 'the Group'), its associate and its joint venture, for the quarter and six months ended 30 September 2018, has been reviewed by the Audit and Risk Management Committee and approved by the Board of Directors at their meeting held on 9 November 2018. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

The Statement has been subjected to limited review by the statutory auditors of the Company. The review report of the auditor is unqualified.

- 2 The statement of category wise utilisation of net proceeds from Initial Public Offer is:

| Category wise utilisation of net proceeds from Initial Public Offer | (Rs. in Lakhs) | |
|---|--------------------------------|---|
| | Amount proposed to be utilised | Actual utilisation upto 30 September 2018 |
| Purchase of medical equipment | 4,220 | - |
| Investment in IT software, services and hardware | 3,019 | 1,627 |
| Pre-payment of debt | 14,704 | 14,700 |
| General corporate purposes | 1,977 | 1,977 |
| Total | 23,920 | 18,304 |

| Details of unutilised funds as on 30 Sep 2018 | (Rs. in Lakhs) |
|---|----------------|
| Investment in fixed deposits | 2,453 |
| Amount parked in cash credit account | 3,163 |
| Total | 5,616 |

- 3 Exceptional items :

- a During the quarter ended 30 September 2017, investment in HealthCare Global (Africa) Private Limited, is accounted under equity method as per Ind AS 28 'Investment in Associates and Joint Ventures' on account of change in control and the resultant gain of Rs. 640 lakhs is shown under exceptional items.
- b During the year ended 31 March 2018, the Company has entered into a business transfer agreement with Strand Life Sciences Private Limited ('Strand') dated 2 January 2018 for sale of its Triesta unit on slump sale basis for a lumpsum consideration of Rs. 2,400 lakhs for which the consideration is received in the form of 9,140,342 equity shares and 101,193 Series 1 Preference Shares of Strand. Pursuant to the same, Strand has become an Associate of the Company effective 7 February 2018. The gain on slump-sale (after eliminating inter-company gain) is Rs. 380 lakhs.
- c During the year ended 31 March 2018, the Delhi unit of the Company became non-operational. Net charge on account of write off of receivables is Rs. 218 lakhs and the charge due to write off of net fixed assets is Rs. 546 lakhs. The total charge due to this unit closure is Rs. 764 lakhs.
- d During the year ended 31 March 2018, in accordance with the terms of share purchase agreement entered into with Regency Hospital Limited dated 28 March 2018, the Company sold its long-term investments in equity shares held in its subsidiary, HCG Regency Oncology Healthcare Private Limited ('HCG Regency') for a total consideration of Rs. 2,123 lakhs resulting in a gain of Rs. 821 lakhs. Pursuant to the above, HCG Regency has ceased to be subsidiary of the Company.

On account of a,b,c and d above, there is an exceptional gain of Rs. 640 lakhs during the quarter ended 30 September 2017 and Rs. 1,077 lakhs during the previous year ended 31 March 2018

- 4 During the year ended 31 March 2018, the Company has entered into a business transfer agreement with Dr. Gopichand ('Seller') dated 28 February 2018 for purchase of business undertaking owned and operated by the Seller in the name of City Cancer Centre ('CCC') located in Vijayawada. The Company has purchased the business on a slump sale basis for a sum consideration of Rs. 5,200 lakhs by issue of equity shares of the Company for Rs. 2,998 lakhs and the balance through cash. Accordingly, 934,500 equity shares of Rs. 10 at premium of Rs. 311 per share has been allotted to Dr. Gopichand, during the preceding quarter ended 30 June 2018 on preferential basis.
- 5 During the quarter ended 30 September 2018, Apex Criticare LLP, holding 49.90% stake in one of the subsidiary of the Company, Apex HCG Oncology Hospitals LLP (Apex LLP) retired from Apex LLP. Pursuant to this, the Company along with its wholly owned subsidiary, Niruja Product Development and Healthcare Research Private Limited holds 100% interest in Apex LLP.
- 6 The Group has a single operating segment of 'setting up and managing hospitals and medical diagnostic services'.
- 7 Effective 1 April 2018 the Group has adopted Ind AS 115 - 'Revenue from Contracts with Customers' using the cumulative effect method. Accordingly, comparative periods were not restated. Based on the assessment, there is no material impact consequent to adoption of the standard.

Bengaluru, 9 November 2018



For and on behalf of the Board of Directors

Dr. B. S. Ajaikumar
Chairman and CEO

